Business Context and Reporting Period
Estrella Immunopharma, Inc. (ESLA) filed a Form 8-K on August 17, 2026, reporting a notice from The Nasdaq Stock Market LLC regarding non-compliance with listing standards. The company is an emerging growth company incorporated in Delaware with principal offices in Emeryville, California.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance triggering the listing notice: the closing bid price of the Common Stock was below $1.00 per share for 30 consecutive business days from July 6, 2026, through August 14, 2026.
Material Changes
The material change reported is the receipt of a formal notification from Nasdaq indicating the company no longer complies with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading of the Common Stock continues on The Nasdaq Capital Market under the symbol "ESLA" pending compliance actions.
Guidance, Outlook, and Risks
- Compliance Period: The company has an initial 180-calendar-day compliance period ending February 16, 2027, to regain compliance.
- Remediation Requirements: To regain compliance, the closing bid price must reach at least $1.00 per share for a minimum of ten consecutive business days. If a reverse stock split is utilized, it must be completed no later than ten business days before the compliance date.
- Future Options: If compliance is not met by the deadline, the company may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of its intent to cure the deficiency.
- Risks: There is no assurance the company will regain compliance. Failure to do so could result in delisting, subject to an appeal process.
Investor Verification Checklist
- Verify the current closing bid price of ESLA to assess proximity to the $1.00 threshold.
- Monitor for announcements regarding a potential reverse stock split before the February 16, 2027 deadline.
- Review subsequent filings for updates on the company's plan to regain compliance or appeals filed with Nasdaq.
- Confirm the status of the company's other Nasdaq listing requirements (e.g., market value of publicly held shares) in case a second compliance period is sought.